The approval landed without fanfare. The market’s reaction, however, told a more complicated story about where BioNTech’s value now truly resides.
US regulators cleared the updated Covid-19 vaccine from Pfizer and BioNTech for the 2026/27 season on Thursday, a routine seasonal milestone that nonetheless carries outsized weight for a company still leaning heavily on its pandemic-era franchise. The shot, targeting the dominant XFG variant, was authorized for adults 65 and older and for those aged 5 to 64 with risk factors, with shipping set to begin immediately.
Yet the real fireworks came from a competitor’s laboratory. A Phase 3 success for Moderna and Merck’s mRNA cancer therapy intismeran sent BioNTech shares surging as much as 21.6 percent on Thursday, as investors read the rival’s breakthrough as validation for the entire mRNA oncology concept — including BioNTech’s own pipeline.
A Rally Built on Borrowed Momentum
The sympathy rally underscores how dramatically the investment thesis has shifted. BioNTech closed Thursday at 95.55 euros, roughly 10 percent shy of its 52-week high of 105.80 euros set in January, and a full 40 percent above the March trough of 68.35 euros. The stock has gained 17 percent since the start of the year and 18 percent over the past 30 days.
That optimism, though, is colliding with a deteriorating core business. The company now guides for 2026 revenue between 1.6 and 1.9 billion euros, a sharp cut from the 2.0 to 2.3 billion euros previously promised. The revision, announced in August, has tempered enthusiasm for the FDA’s seasonal green light, a reminder that vaccination rates continue to erode the franchise’s structural appeal.
The numbers paint a stark picture of a company in transition. Second-quarter 2026 revenue came in at just 105.6 million euros against an IFRS net loss of 820.8 million euros, more than double the 386.6 million euro loss recorded in the same period last year. Research and development spending climbed to 551.0 million euros as the company funnels resources into its oncology ambitions.
Should investors sell immediately? Or is it worth buying BioNTech?
A Pipeline That Demands Patience
BioNTech’s own cancer programs are advancing, though on timelines that test investor patience. The company is running 14 pivotal studies and expects three late-stage data readouts in 2026, including an interim analysis for BNT113. Its lead personalized candidate, autogene cevumeran, is being studied in mid-stage trials against colorectal and pancreatic cancers, with initial colorectal results not expected until 2027 and pancreatic data even later, in 2031.
The company’s balance sheet provides the runway for these long horizons: 16.6 billion euros in cash at the end of June offers substantial room to fund the capital-intensive pipeline without immediate fundraising pressure.
Analysts Divided on the Right Price
The market’s uncertainty over how to value this hybrid story — a shrinking vaccine business alongside a promising but distant oncology pipeline — is reflected in divergent analyst targets. Morgan Stanley’s Terence Flynn issued a buy rating with a 115-dollar price target, while Deutsche Bank Research’s Emmanuel Papadakis reaffirmed his own buy recommendation at a considerably more ambitious 140 dollars.
The gap speaks to how differently investors can weigh the same evidence. Recent weeks have seen the stock swing on leadership news and earnings: the appointment of a new chief executive roughly a month ago lifted shares 11.9 percent, while the quarterly results three weeks prior added another 13.3 percent. The FDA approval, by contrast, has so far failed to generate a comparable impulse.
Institutional interest is building nonetheless. Twenty-nine hedge funds held positions in BioNTech shares at the end of the first quarter, drawn by the pipeline narrative. The stock’s 30-day volatility sits at 69 percent annualized — a measure of just how much the market expects the coming months to move the needle.
The next tangible catalyst arrives on November 2, 2026, when the company reports third-quarter results. By then, investors will have a clearer sense of whether the freshly approved vaccine variant can cushion the year’s weaker revenue trajectory — or whether the oncology story alone must carry the weight of the valuation.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from August 28 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 28.
BioNTech: Buy or sell? Read more here...
